
AstraZeneca’s (AZN) Biologics License Application, BLA, for sonesitatug vedotin, Sone-Ve, has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AZN | AstraZeneca | 174.35 | -5.14 | -2.86% |
| Name | Price | % Change | |
|---|---|---|---|
| $174.35 | -2.86% |

AstraZeneca’s (AZN) Biologics License Application, BLA, for sonesitatug vedotin, Sone-Ve, has been accepted and granted Priority Review in the US for the 2nd and later-line treatment of patients with locally

Alexion and AstraZeneca (AZN) Rare Disease’s Klygefa has been approved in the European Union, EU, as an add-on to standard therapy for the treatment of generalised myasthenia gravis, gMG, in

AstraZeneca ( ($GB:AZN) ) has issued an announcement. The FDA approved AstraZeneca’s Imfinzi (durvalumab) with neoadjuvant enfortumab vedotin, followed by Imfinzi monotherapy after radical cystectomy, for adults with muscle-invasive bladder

The latest update is out from AstraZeneca ( ($GB:AZN) ). Alexion, AstraZeneca Rare Disease’s Klygefa has received EU approval as an add-on to standard therapy for adults with AChR-antibody-positive generalised

AstraZeneca ( ($GB:AZN) ) has issued an announcement. Klygefa (gefurulimab) is a dual-binding nanobody C5 inhibitor administered weekly through a subcutaneous autoinjector. In the US, it is the first and

AstraZeneca ( ($GB:AZN) ) has provided an update. The EMA’s CHMP recommended Baxfendy for EU approval for adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicines. In

AstraZeneca’s (AZN) imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by imfinzi monotherapy as adjuvant treatment after radical cystectomy, has been approved in the US for the treatment

Klygefa is indicated for the treatment of generalized myasthenia gravis in adult patients who are antiacetylcholine receptor antibody positive, according to prescribing information posted to the agency’s website. Published first

The Food and Drug Administration said it approved AstraZeneca’s (AZN) Imfinzi in combination with enfortumab vedotin-ejfv as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment after radical cystectomy,

AstraZeneca (AZN) cut about 600 jobs from its respiratory and immunology commercial teams in the U.S., Ashleigh Furlong of Bloomberg reports, citing people familiar with the matter. Some of cut
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 17, 2026 | ||||
| hold | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 3, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Nov 2, 2026 | ||||
| buy | Reiterated | Oct 30, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 11, 2027TBA | $269.88B | $2.32 | $16.61B | 0.58 | 24.64 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.